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ABSTRACT 
Using a genome-wide screen of 9.6 million genetic variants achieved through 1000 
Genomes imputation in 62,166 samples, we identify association to lipids in 93 loci 
including 79 previously identified loci with new lead-SNPs, 10 new loci, 15 loci with 
a low-frequency and 10 loci with missense lead-SNPs, and, 2 loci with an 
accumulation of rare variants. In six loci, SNPs with established function in lipid 
genetics (CELSR2, GCKR, LIPC, and APOE), or candidate missense mutations with 
predicted damaging function (CD300LG and TM6SF2), explained the locus 
associations. The low-frequency variants increased the proportion of variance 
explained, particularly for LDL-C and TC. Altogether, our results highlight the 
impact of low-frequency variants in complex traits and show that imputation offers a 
cost-effective alternative to re-sequencing.   
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Genome-wide association (GWA) studies have been successful in identifying genetic 
loci associated with complex diseases and traits. Due to the design of genotyping 
arrays, most of the associated variants have been common in population samples. 
While thousands of loci have been associated with complex diseases and traits, they 
so far typically explain only a fraction of the heritability1.  
It has now become possible to search for associations with variants that are less 
frequent than in previous GWA studies by the analysis of large numbers of samples 
using whole genome or exome sequencing approaches. However, costs have so far 
limited the possibility for sequencing of tens of thousands of samples likely needed to 
detect significant associations for low-frequency variants.  
Stochastic imputation to individuals genotyped using genotyping arrays in large 
enough samples offers an alternative and cost-effective design to study associations of 
low-frequency and rare variants at a genome-wide level. GWA studies of circulating 
lipids have been highly successful in identifying loci with common variants with 
small effects2,3. In previous large scale GWA studies, 157 loci have been shown to 
associate with lipids2,3, but the strongest associations have almost exclusively been 
reported with common variants (minor allele frequency, MAF > 5 %) in European 
datasets due to the study designs.  
In contrast, previously published variants known to cause Mendelian forms of 
dyslipidemic syndromes and, more broadly, variants with known functional impact on 
lipids (FL SNPs) typically have low MAF (≤ 5%). While there are almost 40 loci 
where both FL SNPs and common SNPs, implicated in GWA studies, reside, it is 
often not known if these associations are driven by the same underlying haplotypes 
and if the Mendelian variants explain the association in population samples.  
We sought to evaluate the impact of common (MAF > 5%), low-frequency (0.5% < 
MAF ≤ 5%) and rare (MAF ≤ 0.5%) genetic variants on circulating blood lipids in up 
to 62,166 European samples by imputing variants into the GWA cohorts using the 
sequence-based 1000 Genomes reference panel4 (Phase I interim release, June 2011). 
We aimed to answer the following questions: 1) what is the role of low-frequency and 
the burden of rare variants in the established lipid loci, 2) can a dense set of markers 
from 1000 Genomes-based imputation help to identify additional loci undetected in 
previous studies focused largely on common variants imputed up to less dense 
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reference panels from the HapMap-project, 3) how do low-frequency and FL variants 
contribute to the overall trait variance compared to common variants. 
RESULTS 
Study Overview 
To understand the contribution of low-frequency and rare genetic variation to 
circulating lipid concentrations, we undertook genome-wide imputation and 
association analysis in up to 62,166 individuals across 22 GWA cohorts of European 
ancestry. Within each cohort, we performed sex-stratified inverse-rank normalisation 
of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol 
(LDL-C), triglycerides (TG) and total cholesterol (TC), after adjustment of each trait 
for age, age2, and study-specific covariates, including principal components to 
account for population structure. Case-control studies were further sub-divided 
according to original data selection disease status. Each cohort GWA genotype 
scaffold was imputed at up to ~37.4 million autosomal variants from the 1000 
Genomes Project multi-ethnic reference panel4 (Phase I interim release, June 2011). 
Across a subset of studies, ~98% and ~95% of variants present in the reference panel 
with 1% < MAF ≤ 5% and 0.5% < MAF ≤ 1%, respectively, were well imputed, 
defined here by an IMPUTE5,6 info score of at least 0.4 (Supplementary Table 1). 
However, as expected, imputation of rare variants (MAF ≤ 0.5%) proved more 
difficult, although ~65% of the rare variants polymorphic in the reference dataset 
were well imputed across the same subset of studies. 
Genome-wide screen for single variant associations 
We first tested for association of over 9.6 million genotyped or successfully imputed 
SNPs, enabled by the 1000 Genomes imputation, with circulating HDL-C, LDL-C, 
TG and TC levels. Overall, we detected 93 loci with genome-wide significant 
association (Supplementary Figure 1) to one or more lipid traits (p-value < 5×10-8), 
of which 10 loci have not been associated to lipids before (Table 1, Supplementary 
Figures 2A-J and Supplementary Figures 3A-J). Out of the 83 previously 
established lipid loci, 79 had a novel lead-SNP for at least one lipid trait in our 
analysis (Supplementary Table 2). In 34 out of the 79 loci the linkage disequilibrium 
(LD) is r2 ≤ 40% (15 loci with r2 ≤ 5%) and in 56 loci the newly identified variant has 
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not been present in HapMap2 imputation reference set used in previous studies. In 11 
loci the novel lead-SNP had MAF ≤ 5% and an average effect size of 0.18 (in 
standard deviation, s.d., units) compared to the average effect size of 0.05 for the 
previously established common lead-SNP estimated in a cohort independent of the 
discovery scan to avoid bias due to the winner’s curse (N = 5,119, Figures 1A-B). 
These include well-known lipid gene LPA for LDL-C (rs186696265, MAF = 0.8%, 
effect size = 0.26, p-value = 4.4×10-14, r2 = 0.1%). In addition we observed high effect 
lead-SNPs in PCSK9 for LDL-C (rs11591147, MAF = 1.9%, effect size = 0.53, p-
value = 2.2×10-92 and r2 = 0.9%) and APOE for TC (rs7412, MAF = 7.1%, effect size 
= 0.41, p-value = 7.5×10-239 and r2 = 1.6%) that were highlighted already in the 
Global Lipids Genetics Consortium fine-mapping analyses3.  
Using a formal conditional analysis, in MAFB locus, the new low-frequency lead-SNP 
with large effect size (effect size > 0.2 and MAF ≤ 5%) explained the association of 
the previously identified lead-SNP in seven population cohorts (N = 12,834) though 
the linkage disequilibrium between the variants was less than r2=5% (Figures 1A-B). 
Additionally, there were 7 loci with two or more association lead-SNPs over 1Mb 
apart and with r2<5%, but in all cases the individual level formal conditional analyses 
showed that the associations were completely explained by the known lipid SNPs in 
the regions (ZCCHC11, TMEM48 and PPAP2B associations explained by rs11591147 
in PCSK9 locus, OR-cluster association by rs7395581 in LRP4-MADD locus, 
CCDC79 association by rs73591976 in LCAT-RANBP10 locus, and PSG9 and 
IRF2BP1 associations by rs7412 in APOE locus).  
In five of the 79 loci, the lead-SNP was a missense variant pointing to either a well-
established causal gene (ANGPTL4, APOE, PCSK9 and CILP2) or to a new candidate 
gene (ABCA6/8). The APOE lead-SNP for TC, rs7412 (Arg176Cys, MAF = 7.1%, r2 
= 0.7%) has been shown to associate with recessive familial type III 
hyperlipoproteinemia7,8 and the PCSK9 lead-SNP for LDL, rs11591147 (Arg46Leu, 
MAF = 1.9%, r2 = 0.9%), with extreme LDL-C values9. In the ANGPTL4 locus, the 
lead-SNP in our GWA data is a predicted damaging missense variant, rs116843064 
(Glu40Lys, MAF = 3.0%) with r2 = 1.8% with the previously associated common 
lead-SNP. The missense variant is associated with TG and HDL-C, and has 
previously been associated with extreme TG values10. The CILP2 lead-SNP, 
rs58542926 (Glu167Lys in TM6SF2 gene, MAF = 7.8%, r2 = 98%), was associated to 
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TC, myocardial infarction risk, and nonalcoholic fatty liver disease in two papers 
appearing while revising this manuscript11,12. Our new lead-SNP in ABCA6/8 locus, 
rs77542162 (Cys1359Arg in ABCA6 gene, MAF = 2.0%, r2 = 0.6%) associates with 
LDL-C and TC (p-value = 1.6×10-18 and p-value = 1.9×10-13, respectively).  
In the genome-wide screening we identified 10 loci that have not previously been 
associated to lipids (near PROX1, CEP68, PRKAG3, ADAMTS3, MTHFD2L, GPR85, 
RMI2, TM4SF5, GATA6 and ZNF274), with 4 having a low-frequency variant (MAF 
< 5%) as the lead-SNP (lowest MAF = 0.7% rs182616603 in MTHFD2L locus; Table 
1). All except one of the lead-SNPs have not been surveyed in the previous GWA 
studies based on HapMap 2 imputation. The one lead-SNP that has been present in the 
HapMap 2 imputation references is in the PROX1 5’UTR (rs340839 associated with 
TG, p-value = 4.4×10-12) and is correlated with a marker previously associated with 
fasting glucose and type 2 diabetes13 (rs340874, r2 = 74.7%). The lead-SNP in the 
HDL associated PRKAG3 locus is located upstream to the gene, close to a 
transcription factor binding site. PRKAG3 is a regulatory subunit of the AMP-
activated protein kinase (AMPK), which has previously been shown to regulate lipid 
homeostasis14.  
The role of variants with known functional impact on lipids in the general 
population 
In 8 loci (PCSK9, CELSR2-SORT1, GCKR, HLA-region, LPL, LIPC, CETP and 
APOE), we tested if the variants known to cause Mendelian forms of dyslipidemic 
syndromes and, more broadly, with known functional impact on lipids, also explained 
the associations of the common lipid SNPs. These FL SNPs were identified through 
the Online Mendelian Inheritance in Man database search (OMIM; www.omim.org) 
and confirmed through literature, and SNPs previously reported to affect gene 
transcription or translation in cellular and/or animal models were taken forward into 
conditional analyses in seven population cohorts (N = 12,834; Supplementary 
Figure 4, Supplementary Table 3 and Supplementary Table 3).  
The FL SNPs explained the lead-SNP association (with p-value < 5×10-8 and 
conditional p-value > 0.01 for the lead-SNP) in four of the 8 loci (CELSR2-SORT1, 
GCKR, APOE and LIPC; Table 2, Supplementary Figures 5A-G). In GCKR and 
APOE loci, the lead-SNPs of our GWA screen were FL SNPs (rs126032615; 
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Pro446Leu and rs74127,8; Arg158Cys, for GCKR and APOE, respectively). In the 
GCKR locus, rs1260326 explained the population-level association. Similarly, in 
APOE locus, the two FL SNPs rs7412 and rs42935816 (Cys112Arg) defining the 
APOE isoforms ε2, ε3 and ε417 explained the association (Supplementary Figures 
5D and 5E). The LIPC association was explained by rs180058818 (-514C-T, MAF = 
25.1%) and rs11329816419 (Thr383Met, MAF = 1.4%) for TC and TG 
(Supplementary Figures 5F and 5G) but not for HDL-C (Supplementary Figure 
5H). All results for the conditional analyses are presented in Supplementary Tables 
5A-D. 
Search for novel functional candidate SNPs 
We then searched for potential candidate causal SNPs in the lipid-associated (157 
established and 10 novel) loci with a similar predicted function to well-characterized 
FL SNPs. We identified possible functional variants in four loci without known 
functional variants at the time of analysis (MLXILP, LRP4-MADD, SOST-DUSP3 and 
CILP2), and tested whether the identified variants explained the significant 
association seen in the locus (Supplementary Table 6). The results of the conditional 
regression analyses for these four loci are presented in Table 3 and Supplementary 
Figures 6A-F. In the SOST-DUSP3 and CILP2 loci, the functional candidates 
explained the genome-wide associations of the lead-SNPs in the region in the test set 
(in both loci, conditional p-value > 0.01). In the SOST-DUSP3 locus (Figure 2A), a 
single low-frequency deleterious missense variant, rs72836561 (Arg82Cys, MAF = 
2.7%, p-value = 1.36×10-8, effect size = 0.23) in the CD300LG gene, explained the 
whole regional association indicating CD300LG as a likely candidate gene for TG in 
the locus. The same variant has also recently been shown to associate with HDL-C 
and with fasting serum triacylglycerol in exome-wide association studies20,21. 
In the CILP2 locus for LDL-C, TC and TG, two independent missense variants (r2 = 
0) in the TM6SF2 gene, a deleterious missense variant rs187429064 (MAF = 3.6%, 
Leu156Pro; for TC effect size = -0.25 and p-value = 2.03×10-11) and a probably 
damaging missense variant rs58542926 (MAF = 6.3%, Glu167Lys; for TC effect size 
= -0.18 and p-value = 6.47×10-12), explained the lead-SNP association for LDL-C, TC 
and TG (Table 3, Supplementary Figures 6D-F, and Figure 2B and 
Supplementary Figure 7 illustrates the result of the conditional analysis for TC).   
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Biological profiling of CD300LG and TM6SF2 genes in lipid metabolism 
CD300LG (CD300 Molecule-Like Family Member G; also called nepmucin) is a type 
I cell surface glycoprotein that contains a single immunoglobulin (Ig) V-like domain22 
and plays a role in lymphocyte binding and transmigration23. The predicted damaging 
mutation (Arg82Cys) in our TG/HDL-C -associated variant rs72836561 is located in 
the Ig domain of CD300LG, which binds to lymphocytes. CD300LG is expressed in 
the vascular endothelial cells of various tissues, and is located both at the plasma 
membrane and intracellular vesicles23,24. While CD300 family members have been 
demonstrated to bind lipids25, the function of CD300LG in lipid metabolism has not 
been studied. TM6SF2 (Transmembrane 6 Superfamily Member 2)26, is a multi-pass 
membrane protein, in which the predicted deleterious missense mutation 
(rs1874290064; Leu156Pro) locates to the predicted 5th transmembrane domain, and 
the probably damaging missense mutation (rs58542926; Glu167Lys) in the exposed 
non-transmembrane domain. TM6SF2 gene has been shown to localize to 
endoplasmic reticulum (ER) compartment/ER-Golgi intermediate compartment 
(ERGIC) and influence TG secretion in liver cells27. Additionally, the Glu167Lys 
missense mutation was shown to alter serum lipid profiles in humans and the 
knockdown of TM6SF2 in mice was shown to lead to increased liver triglyceride 
content and decreased very-low-density lipoprotein (VLDL) secretion11,12.  
We further characterized the two genes by using the Gene-Network database28 
(http://genenetwork.nl/genenetwork, see online Methods for details) for tissue 
specific expression, pathway analysis, and prediction of mice knockout phenotype, 
based on Mouse Genome Informatics (MGI; http://www.informatics.jax.org)29. We 
found that CD300LG gene is co-expressed with genes where knockout increases 
circulating very low-density lipoprotein (VLDL) particle levels in mice (prediction p-
value = 1.4×10-9), in line with our phenotype of higher TG levels in humans carrying 
the deleterious missense variant of CD300LG. For TM6SF2, the MGI-based 
predictions, using co-expression of genes, show abnormal lipid levels (decreased 
LDL-C: prediction p-value = 8.6×10-19, decreased VLDL: prediction p-value = 
2.5×10-29 and decreased TC: prediction p-value = 6.3×10-24) amongst the most highly 
significant predictions, in line with the recent publications and our association results. 
All associated MGI-based knockout predictions (p-value < 1e-6) are shown in the 
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Supplementary Tables 7A-B and lists of genes with same and stronger MGI-based 
predictions can be found in the Supplementary Table 8.    
Both genes were found to be amongst the most highly expressed genes in tissues 
important for lipid absorption and/or metabolism based on the analysis using the Gene 
Network database (Supplementary Tables 9A-B). CD300LG is highly expressed in 
muscles, plasma, and adipose tissue and TM6SF2 in liver, plasma, and intestines. 
Furthermore, based on the gene expression network analysis, TM6SF2 likely interacts 
with proteins involved in intestinal absorption (Supplementary Table 10), and it is 
most highly predicted to function as lipid transporter (p-value = 1.05×10-14, 
prediction is based on co-expressed genes, Supplementary Table 11). 
Contribution of low-frequency variants to population lipid variation 
We estimated the proportion of the variance of lipid traits explained by variants in the 
157 previously established and 10 novel loci in an additional cohort of 5,119 
individuals from Finrisk cohort (FRCoreExome9702), not included in our discovery 
meta-analysis. The lead-SNPs from all three GWA screens (Teslovich et al.2, Willer 
et al.3 and this study) together with the FL SNPs and new functional candidate SNPs 
were divided into two groups based on their allele frequency in the 
FRCoreExome9702 dataset. Common SNPs explained 8.2% (TG), 11.9% (HDL-C), 
16.3% (LDL-C), and 16.2% (TC) of the variance in lipid levels (Figure 3). Together 
with the low-frequency variants we now explain 9.3%, 12.8%, 19.5% and 18.8% of 
the variance in TG, HDL-C, LDL-C and TC, respectively.  
We also compared the contribution of our SNPs to the additive genetic variance 
estimated by a linear mixed model (LMM) applied to 10,472 individuals from six 
Finnish GWA cohorts (Online Methods) with those obtained from a large twin 
study30. The narrow sense heritability estimates from the twin study were 40%, 51%, 
51% and 33% and the mixed linear model estimates derived from the Finnish subset 
were 26%, 29%, 27% and 19% (for HDL-C, LDL-C, TC and TG, respectively. See 
Online Methods for details). We estimate that the SNP set explain at least 28.1%, 
32.0%, 38.2% and 36.7% (narrow sense heritability) and at most 48.9%, 49.2%, 
67.2% and 69.6% (LMM heritability estimate) of the additive genetic variance of TG, 
HDL-C, LDL-C and TC, respectively.  
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Gene-based association analysis 
To complement the single-variant tests for low-frequency variation we used 
GRANVIL31 to test for association of each lipid trait with accumulations of minor 
alleles (“mutational load”) at well imputed rare variants within genes in a subset of 
30,463 individuals from 15 cohorts (Online Methods, Supplementary Table 1).  
We observed genome-wide significant evidence of association (p-value < 1.7×10-6, 
Bonferroni correction for 30,000 genes) of HDL-C with the mutational load of rare 
non-synonymous variants in LIPC (p-value = 2.1×10-7, mean MAF = 0.26%, 
Supplementary Figure 8). To further investigate the relationship between gene-
based and single SNP association signals at this locus, we performed conditional 
analysis, adjusting the effect of the mutational load for the lead-SNP in our study 
(rs261291). The association of HDL-C with rare non-synonymous variants in LIPC 
remains relatively unchanged (conditional p-value = 3.6×10-6), suggesting that the 
mutational load of the gene is independent of the GWA signal at this locus. 
We identified two genes for which the mutational load of rare variants (irrespective of 
annotation) was associated with TG at genome-wide significance, both mapping to 
the APO-cluster: ZNF259 (p-value = 1.5×10-11, mean MAF = 0.25%) and APOA5 (p-
value = 5.0×10-8, mean MAF = 0.24%). Conditional analyses, adjusting for the 
association lead-SNP (rs964184) at the APO-cluster, reduced the strength of 
association of rare variants in both ZNF259 and APOA5 with TG, but could not fully 
explain the effect of the mutational load of these genes (Supplementary Table 12). 
As ZNF259 and APOA5 map within 2kb of each other, we further investigated the 
impact of LD on the association signal at the region with conditional analyses 
adjusting for the mutational load of each gene for that at the other (Online Methods). 
The strength of association of both genes was reduced, but not fully attenuated, after 
adjusting for the effect of the other (ZNF259 conditional p-value = 1.4×10-5; APOA5 
conditional p-value = 6.3×10-4), suggesting the effects of rare variants in these two 
genes to be only partially correlated with each other. 
DISCUSSION  
Using 1000 Genomes imputed data with a dense SNP set, we were able to impute 
9.6M common and low-frequency SNPs with good quality in 62,166 European 
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samples. With GWA meta-analysis on these data, we identified 10 novel loci 
associated to blood lipids and new lead-SNPs in 79 previously known lipid loci. In 11 
previously known loci, the new lead-SNP had a minor allele frequency ≤ 5% and, on 
average the newly identified low-frequency variants showed 3.6 times larger effect 
size compared to the corresponding lead-SNP in previous meta-analysis studies. 
Moreover, in four of the ten novel loci, the lead-SNPs were low-frequency variants.  
Our association results reveal that low-frequency variants have a much larger 
contribution to lipid variation in the general population than has previously been 
shown2,3. In several cases, the association that has previously been tagged by common 
variants is now led by variants with 0.5 − 5% allele frequency and larger effect sizes. 
The large effect sizes also show in the population lipid variance explained, where 
low-frequency variants add 3.2% to the LDL-C variance explained when adding on 
top of the common variants identified in previous reports or in our study, even though 
there are relatively few carriers of low-frequency variants in the general population.  
While GWA studies have typically identified associations to lipid levels in cohorts 
with normal population variation, the known functional variants, some causing 
Mendelian forms of lipid syndromes and others changing the protein structure or 
disturbing the gene transcription, often been identified in patients and families with 
extreme lipid values. We found four regions where the population-level association 
was explained by known Mendelian and/or functional SNPs, suggesting that the 
effects of FL SNPs seem to generalize to European samples with normal lipid 
variation. Taken together, the successfully imputed and tested functional SNPs 
together with the new functional candidate variants explained 2.2 − 6.7% of the lipid 
variation in the population level.  
As the FL SNPs explained the population-level association in four of the studied eight 
loci through LD-structure, we reversed this connection to identify potential functional 
candidate genes through SNPs with similar functional profile to the FL SNPs in lipid 
loci with no previous strong functional candidates. Using this strategy we identified 
two loci where missense variants with predicted damaging or deleterious functions 
explained the lead-SNP associations from the GWA meta-analysis, thus, together with 
previous evidence, supporting the role of CD300LG (TGs) and TM6SF2 (TC, LDL-C, 
TGs) in lipid metabolism together with evidence from gene network analysis, gene 
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expression correlations, predicted functions in mice, and expression patterns across 
organs each suggest potential links to lipid metabolism. TM6SF2 was recently listed 
among genes potentially affecting LDL-C uptake in a recent siRNA screen focused on 
cellular lipid phenotypes within previously published blood lipid-associated GWA-
loci.32 Additionally, two reports showing strong evidence for one of the two TM6SF2 
missense variants, Glu167Lys, on VLDL and TG metabolism were published during 
this study11,12. However, in our data, this mutation alone does not explain the whole 
regional association, but together with a second missense mutation, with lower MAF 
and larger effect, the association was explained. Overall, our results reinforce the 
importance of CD300LG and TM6SF2 for blood lipid levels in the general population.  
In two established GWAS loci with common lead SNPs, our analyses revealed 
associations of the mutational load of rare variants with lipids.  The association of 
HDL-C with rare variants in LIPC has been previously reported33, and we also 
demonstrate that this signal is independent of the common lead GWAS SNP at this 
locus.  We identified association on TG for the accumulation of APOA5 rare variants 
as significant, but conditional analysis on the GWAs lead-SNP suggested that the 
single variant and gene-based associations are partially correlated. However, the 
GWA lead-SNP alone was not sufficient to fully explain the gene-based signal. An 
excess of minor alleles in APOA5 has previously been associated with 
hypertriglyceridemia34, but we report here an impact of this gene on TG at a 
population level.  Although imputation enables recovery of ~65% of rare variants that 
are present in the 1000 Genomes haplotypes, many will not be represented in the 
reference panel.  Re-sequencing in large sample sizes will be required to fully 
elucidate the role of rare variation at these GWA loci on HDL-C and TG and to 
inform functional studies to determine the underlying mechanisms mediated through 
these genes for the regulation of lipids. 
In addition to the 93 loci identified, there were seven loci showing two or more 
association signals that were more than 1Mb distance from each other and the linkage 
disequilibrium between the lead SNPs were small (r2 ≤ 0.05). However, in formal 
conditional analyses of these loci using individual level data the most strongly 
associated SNPs in the locus explained also the other associations, even over a 
physical distance of 1Mb or more, or low level of LD. As these observations were 
only revealed after careful conditional testing of individual level data, they also 
! 16!
highlight how challenging it is to interpret the association patterns using only 
summary level results on single SNP analyses. 
There are some potential limitations to our genetic study. Although we used a dense 
sequence-based global imputation panel, it does not cover all low-frequency and rare 
variants in Europe. Similarly, although the imputation reference set included a large 
number of low-frequency SNPs and other variants with known functional impact on 
lipids, some were either missing from the panel or they were not polymorphic in our 
test sets of seven Finnish cohorts. Therefore we are likely missing some additional 
effects in our data. As more individuals are being sequenced and made available as 
imputation reference panels, more variants can also be imputed with high confidence 
and tested for associations.  
In conclusion, our study shows that low-frequency variants contribute significantly to 
population variance in lipid levels. The variants known to cause Mendelian forms of 
lipid syndromes and variants with known functional effects on lipid levels explain the 
common variant association in overlapping loci revealing a similar role of these 
variants in extreme patient series and in general populations. In addition, we found 10 
new lipid loci for further investigations and for two previously known lipid loci we 
identified new candidate missense variants with predicted damaging function. When 
combining all the accumulated genetic evidence, we could explain up to 19.5% of the 
trait lipid variation. By considering the aggregate effects of rare variants within genes, 
we identified three transcripts associated with lipids in already established GWA loci 
that could not be fully explained by the common lead-SNPs reported in this study. 
Together, these observations show the important role of low-frequency functional 
SNPs in lipid level variation in the general population and present new therapeutic 
opportunities for treating dyslipidemias and preventing cardiovascular diseases. They 
also highlight that imputation is a cost-effective approach to assessing association 
with low-frequency and rare variants, without the need for costly re-sequencing 
experiments. 
ONLINE METHODS 
Genotype quality control and imputation 
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Before imputation all cohorts (see Supplementary Note for cohort information) went 
through a quality control (QC) pipeline with the following criteria: samples with 
genotype call rate < 95%, sex discrepancies, excess heterozygosity and cryptic 
relatedness were removed. Additionally, ethnic outliers and MDS outliers were 
excluded. SNPs with minor allele frequency (MAF) < 1%, call rate < 95% (or < 99% 
if the SNP has MAF < 5%), failure of the Hardy-Weinberg Equilibrium (HWE) exact 
test (precise threshold depending on study) and sex chromosome SNPs were removed. 
Genotyping platforms, study-specific QC criteria and other details are presented in 
Supplementary Table 13. The imputation of the datasets was performed using 
IMPUTE v2.05,6 (unless stated otherwise) with 1000 Genomes June 2011 imputation 
reference panel with 2,188 haplotypes4 (www.1000genomes.org).  
Phenotype measures 
All four lipids, HDL-C, LDL-C, TC and TG were measured using basic enzymatic 
methods. Summary statistics of phenotypes in each cohort are presented in 
Supplementary Table 14. Individuals with lipid-lowering medication were excluded 
and measures deviating more than 5 s.d. were set to missing. All four phenotypes 
were adjusted for age, age2 and the first three genetic principal components. Principal 
components were derived from the GWA data using principal component analysis for 
the IBS sharing matrix for each study separately35. Both the removal of outliers and 
the adjustments were done for males and females separately in each of the studies for 
all four traits. The residuals resulting from the adjustments where then inverse normal 
transformed to the N(0,1) distribution. The GenMets and DGI cohorts were 
additionally stratified by the Metabolic syndrome and Type 2 Diabetes case status, 
respectively. Only men were available in GerMIFS I and II and ULSAM. As NTR has 
related samples, males and females were analysed together in order to account for the 
relatedness. 
Single variant association- and Meta-analysis methods 
A genome-wide association analysis was run in each of the cohorts separately (see 
Supplementary Table 13 for software details). The association results were quality 
controlled centrally to have as harmonized dataset as possible. In the procedure, the 
following SNPs were removed: SNPs with minor allele count < 3; SNPs with 
imputation quality Proper_INFO < 0.4; duplicates; genotyped SNPs with HWE p-
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value < 1×10-4. The meta-analysis was run using the GWAMA software tool36,37, 
which uses fixed-effects inverse-variance weighted meta-analysis. Genomic control 
was applied to each of the cohorts in the meta-analysis. SNPs with < 50% of the 
cohorts contributing or SNPs showing between-study heterogeneity of effect size 
(Cochran ‘s Q test statistics, I2<50%) were discarded from the meta-analysis results. 
After these QC steps, the maximum number of SNPs in the analysis was 9,657,952. 
SNP associations with p-value < 5×10-8 were considered genome-wide significant and 
lead-SNPs were inquired to be at least 1Mb away from adjacent lead-SNPs. In areas 
with long-spanning linkage-disequilibrium, formal conditional analysis was 
performed in a subset of 12,834 Finnish samples to ensure the independence of the 
lead-SNPs.  
Search for known functional lipid SNPs 
We searched the Online Mendelian Inheritance of Man (OMIM; www.omim.org) 
database for information on 167 loci, which had been found to associate with one of 
the studied traits (HDL-C, LDL-C, TC and TG) in either the two previously published 
GWA studies2,3 or in our genome-wide screening. In each of these 167 loci, every 
gene in a 2Mb area around the published lead variant was looked up for in the OMIM 
database and the variants associated with lipid related syndromes or population 
extreme lipid values were collected. Out of the 167 loci, 38 had OMIM-listed lipid 
SNP variants within the searched window. As our genotype data only includes SNP 
variants, deletions, insertions and other copy number variations could not be studied. 
Each of the OMIM-listed lipid SNPs was subsequently mapped to genome build 37 
using dbSNP database for the rsID identification. Of the 38 loci, 18 had at least one 
polymorphic OMIM SNP in the imputed Finnish test set of seven cohorts (Corogene 
controls, FTC, GenMets, HBCS, NFBC1966, YFS and PredictCVD, combined N = 
12,834). To be sure about the functionality of these SNPs, additional literature search 
was performed to find evidence of the effect on gene transcription or translation. Out 
of the 18 loci, 8 showed genome-wide significant association in the Finnish meta-
analysis and had at least one variant with evidence for functional impact on lipid 
levels in cell or animal models. 
Formal conditional association analysis in loci containing known functional lipid 
SNPs 
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Formal conditional analyses were run using the Finnish test set of 7 cohorts (N = 
12,834). Each of the cohorts was analysed separately with linear regression analysis 
implemented by SNPTest software 
(http://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html). In each cohort, 
imputation quality threshold of Proper_INFO > 0.4 was applied. Each locus was 
analysed only for the trait(s) it had been previously reported to associate with in 
already published GWA studies. In the conditional analysis on a particular SNP(s), 
the phenotype was first adjusted with the SNP(s) and then a linear regression model 
was fitted for the remaining residuals. When we performed iterative conditional 
analyses in a locus, the signal was first conditioned on the most significant variant 
followed by conditioning on the top variant from the initial conditional analysis and 
so forth. Loci where the initial lead-SNP association in the conditional analyses was 
conditional p-value < 0.01 and no further significant associations (conditional p-value 
< 5×10-8) were found within the 2Mb window were considered to be explained. 
The results from the seven Finnish cohorts were combined using GWAMA. Because 
the conditional analyses were run for the pre-selected 2Mb windows only, genomic 
inflation factor (λ) correction could not be applied. However, we did not see 
substantial inflation in the genome-wide association analysis of all four traits in the 
seven Finnish cohorts (λ range 0.992 − 1.029 depending of the trait and cohort). 
Search for functional candidate SNPs 
In order to explore suggestive functional variants causing association signals, which 
do not have lipid related OMIM listed variants in the locus, we selected 9 loci: 
GALNT2, MLXILP, PPP1R3B, TRIB1, ADAMTS3, LRP4-MADD, SOST-DUSP3, 
CILP2 and HNF4A. These loci had been significantly associated with lipid traits in 
either previously published GWA studies2,3 or in our genome-wide screening as well 
as in the meta-analysis using 7 Finnish cohorts (N = 12,834). In each of these loci, 
2Mb windows were searched for functional variants that had association p-value < 
5×10-4. Candidate SNPs were annotated using the Ensembl database and functional 
effects were predicted using the Provean38, SIFT39 and PolyPhen40 databases. If a 
variant was annotated as a missense mutation with damaging prediction in at least one 
of the prediction databases, it was treated as a FL variant and formal conditional 
analysis was performed to investigate if it explains the association. 
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Gene-network analysis 
We used 2,206 principal components that had been derived from 77,840 Affymetrix 
microarrays (54,736 human, 17,081 mouse and 6,023 rat). Since gene-set enrichment 
analysis showed that each of these components are enriched for at least one biological 
pathway we used these components to developed a gene function prediction 
algorithm. To do so we first determine whether each of the components are enriched 
for a given gene-set, by performing a T-test (contrasting genes, known to be part of 
this pathways with all other genes), and transform the T-statistics into Z-scores. 
Subsequently we can the eigenvector coefficients of the 2,206 components for 
individual genes of interest with the Z-score profile of this gene-set, to predict the 
gene’s involvement in a specific pathway (details provided in Fehrmann et al.28, see 
Cvejic et al.41 and Wood et al.29 for a short description). We used a permutation 
strategy to determine significance of the predictions, controlling the false discovery 
rate at 5%. See http://genenetwork.nl/genenetwork for the predictions. Based on the 
Mouse Genome Informatics (MGI; http://www.informatics.jax.org) mouse knockout 
database, we predicted CD300LG to increase circulating VLDL cholesterol levels. 
For TM6SF2, the most significantly predicted biological process was intestinal 
absorption. Only highly significant predictions (permuted p-value < 1×10-6) were 
taken into account when profiling the two genes. 
We text-mined the sample descriptions provided by the experimenters who uploaded 
the microarray data to GEO. This text mining allowed us to determine the tissue or 
cell type for the majority of the samples. We subsequently used Wilcoxon-Mann-
Whitney tests in the human samples from the Affymetrix U133 Plus 2.0 platform to 
ascertain how highly each gene was expressed in samples of a certain tissue or cell 
type as compared to samples in other tissues and cell types. We found that CD300LG 
is highly expressed in adipose tissue, heart, muscle and plasma and that TM6SF2 is 
highly expressed in ileum and intestinal mucosa. See 
http://genenetwork.nl/genenetwork for the expression of genes in different tissues and 
cell types. 
Modelling proportion of variance explained  
To estimate the phenotypic variance explained by different types of SNPs we ran 
multiple linear regression models in R42 using the FRCoreExome9702 dataset (N = 
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5,119), an independent sample set from the Finrisk cohort. For the models all lead-
SNPs (Teslovich et al.2, Willer et al.3 and our study) together with FL SNPs and new 
functional candidates were divided into two groups based on the MAF of the variants 
in the FRCoreExome9702 dataset. The tested SNP sets were:  
1. Common (MAF > 5%) lead-SNPs and functional SNPs 
2. Adding low-frequency (MAF ≤ 5%) lead-SNPs and functional SNPs to SNP-
set 1. 
3. FL SNPs and the three identified functional candidates. 
These SNP-sets were used to explain the variation of the sex, age, age2 and population 
stratification adjusted trait residuals. In order to apply linear models, TG was log-
transformed before adjustments.  
Linear mixed model estimate of the variance explained by common SNPs 
We estimated how much phenotypic variance a panel of 319,445 directly genotyped 
SNPs with MAF > 1% in the autosomes explain using the linear mixed model 
approach implemented in GCTA43 (v.1.13). This estimate is a lower bound of the total 
additive genetic variance, because it only includes the contribution of the variants 
tagged by the panel of common SNPs that was used in the analysis. The analysis 
included samples from six Finnish cohorts (NFBC1966, Corogene controls, GenMets, 
YFS, HBCS and PredictCVD) for which we had access to the individual genotype 
data. All mixed model analyses excluded individuals in such a way that none of the 
remaining pairs of individuals had an estimated relatedness coefficient r > 0.05 and 
the same trait values were used as with the individual SNP analyses. The sample sizes 
for the traits were 10,466 for HDL-C, 10,383 for LDL-C, 10,472 for TC and 10,451 
for TG. 
Gene-based association analysis 
Transcript boundaries were defined according to the UCSC human genome database. 
Within each study, GRANVIL31 was used to test for association of each trait with 
accumulations of minor alleles (“mutational load”) at successfully imputed rare 
variants (MAF ≤ 1% and info ≥ 0.4, Supplementary Table 1) within genes in a linear 
regression framework: (i) irrespective of annotation; and (ii) restricted to non-
synonymous changes. Fixed-effects meta-analysis was performed by combining 
! 22!
directed Z-scores from the regression analysis across studies, weighted by sample 
size. The significance threshold was set to p-value < 1.7x10-6 corresponding to a 
Bonferroni correction for 30,000 genes. Conditional analyses were performed to 
assess the evidence of association of traits the mutational load of a gene after 
accounting for the lead-SNP by including the genotype (under an additive model) of 
this variant as a covariate in the regression model. Conditional analyses were also 
performed to assess the independence of effects of rare variants in two genes by 
including the mutational load of one as a covariate in the regression model for the trait 
association with the other. 
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Tables 
Table 1. Newly identified loci associated to HDL-C, LDL-C, TC and/or TG 
Locus CHR 
Position 
B37 
rsID Annotation 
Primary 
associated 
trait 
Secondary 
associated 
trait 
Alleles 
(effect/
other) 
EAF 
Meta-analysis 
Effect SE p-value N 
PROX1 1 214161820 rs340839* UTR5 TG  A/G 0.47 0.039 0.006 4.4×10-10 54836 
CEP68 2 65284623 rs2540948 intronic TG  C/T 0.35 -0.036 0.006 6.6×10-9 59939 
PRKAG3 2 219699999 rs78058190 intergenic HDL-C  A/G 0.05 -0.141 0.020 5.7×10-12 52934 
ADAMTS3 4 73696709 rs117087731 intergenic TC  T/A 0.01 0.308 0.051 2.310-9 23641 
MTHFD2L 4 75084732 rs182616603 intronic 
TC  T/C 0.01 0.374 0.044 1.8×10-17 42905 
 LDL-C T/C 0.01 0.314 0.045 2.1×10-12 38420 
GPR85 7 112722196 rs2255811 UTR3 TG  G/A 0.25 0.041 0.007 2.3×10-8 59962 
RMI2 16 11454650 rs7188861 intergenic HDL-C  A/C 0.20 0.044 0.008 6.9×10-9 60578 
TM4SF5 17 4667984 rs193042029 intergenic TG  G/T 0.01 -0.170 0.029 8.1×10-9 50105 
GATA6 18 19907770 rs79588679 intergenic LDL-C  T/C 0.17 -0.049 0.009 3.6×10-8 53108 
ZNF274 19 
58681861 rs117492019 intergenic LDL-C  T/G 0.19 -0.047 0.008 1.2×10-8 55371 
58671267 rs12983728 intergenic  TC A/G 0.16 -0.046 0.008 4.9×10-8 58904 
* Present in the HapMap 2 reference panel. 
Table presents the association meta-analysis results for the newly identified loci for the four tested lipid traits. Effect sizes are presented in s.d 
units. CHR: Chromosome, EAF: Effect allele frequency, SE: standard error of the effect, N: number of samples, HDL-C: high density lipoprotein 
cholesterol, LDL-C: low density lipoprotein cholesterol, TC: total cholesterol, TG: triglycerides.
! 28!
Table 2. Association results of unconditional analysis and analysis conditional on known Mendelian and functional lipid SNPs in loci where the 
functional SNPs explain the genome-wide association.  
Locus CHR Trait 
Lead-SNP in the unconditional analysis 
rsID MAF 
Unconditional Conditional 
Effect 
(SE) 
p-value     
N 
Covariate SNPs in the 
model 
(MAF) 
Effect 
(SE) 
p-value   
N 
CELSR2-
SORT1 
1 
LDL-C rs646776 0.216 
0.159 
(0.015) 
1.31×10-25 
12739 
rs12740374 (21.6 %) 
0.001 
(0.015) 
0.958 
12739 
TC rs646776 0.216 
0.123 
(0.015) 
4.06×10-16 
12834 
rs12740374 (21.6 %) 
0.001 
(0.015) 
0.959 
12834 
GCKR 2 TG rs1260326 0.353 0.128 
(0.013) 
8.44×10-23 
12815 
rs1260326 (35.3 %) NA NA 
LIPC 15 
TC rs1800588 0.251 
0.090 
(0.015) 
7.23×10-10 
12825 
rs113298164 (1.4 %) 
rs1800588 (25.1 %) 
-2×10-6 
(0.015) 
1.000 
11893 
TG rs686958 0.252 
0.085 
(0.015) 
6.86×10-9 
12801 
rs113298164 (1.4 %) 
rs1800588 (25.1 %) 
0.022 
(0.015) 
0.152 
11873 
APOE 19 
LDL-C rs7412 0.048 
0.648 
(0.031) 
5.93×10-95 
12730 
rs7412 (4.8 %) 
rs429358 (18.1 %) 
NA NA 
TC rs7412 0.048 
0.456 
(0.031) 
3.10×10-49 
12827 
rs7412 (4.8 %) 
rs429358 (18.1 %) 
NA NA 
TG rs483082 0.229 
0.089 
(0.015) 
5.74×10-9 
12799 
rs7412 (4.8 %) 
rs429358 (18.1 %) 
NA NA 
The table shows results for unconditional association analysis and analysis conditional on variants known to cause Mendelian forms of 
dyslipidemic syndromes and, more broadly, variants with known functional impact on lipids (FL SNPs). In case multiple candidate variants were 
observed in a locus, they were all included in the same model. Results for the lead-SNP from the unconditional analysis are presented from the 
meta-analysis of Finnish subset (N = 12,834). Effect sizes are presented in s.d units. CHR: Chromosome, MAF: Minor allele frequency, SE: 
Standard error of effect estimate, N: Number of samples, HDL-C: High-density lipoprotein cholesterol, LDL-C: Low-density lipoprotein 
cholesterol, TC: Total cholesterol, TG: Triglycerides.
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Table 3. Association results of unconditional analysis and analysis conditional on the functional candidate SNPs in four loci with genome-wide 
significant p-value and new functional candidate SNPs. 
Locus CHR Trait 
Testing the lead-SNP effects 
Tested lead-SNP 
rsID 
MAF 
Unconditional Conditional 
Effect 
(SE) 
p-value     
N 
Candidate SNP used as a 
single covariate in the model 
(MAF) 
Lead-SNP 
effect when 
adjusting for 
single SNP 
(SE) 
p-value   
N 
Candidate SNPs used 
jointly as covariates in 
the model 
(MAF) 
Lead-SNP 
effect when 
adjusting for 
multiple 
SNPs (SE) 
p-value   
N 
MLXIPL 7 TG rs35797675 0.174 
-0.119 
(0.017) 
7.89×10-13 
12810 
rs35332062  (12%) 
-0.044 
(0.017) 
0.0073 
12810 rs35332062  (12%) 
rs3812316  (12%) 
-0.044 
(0.017) 
0.0074 
12810 
rs3812316  (12%) 
-0.044 
(0.017) 
0.0073 
12810 
LRP4-
MADD 
11 HDL-C rs2596401 0.426 
-0.092 
(0.013) 
3.55×10-12 
11894 
rs2279238  (27%) -0.039 0.013 
0.0033 
11894 
rs2279238  (27%) 
rs2290148  (27%) 
rs34312154  (20%) 
rs75352463  (3%) 
rs1064608  (36%) 
rs5896  (23%) 
-0.031 
(0.013) 
0.020 
11894 
rs2290148  (27%) -0.040 0.013 
0.0028 
11894 
rs34312154  (20%) -0.060 0.013 
6.0×10-6 
11894 
rs75352463  (3%) -0.077 0.013 
6.4×10-9 
11894 
rs1064608  (36%) -0.060 0.013 
7.1×10-6 
11894 
rs5896  (23%) -0.055 0.013 
3.0×10-5 
11894 
SOST-
DUSP3 
17 TG rs72836561 0.027 
0.234 
(0.041) 
1.36×10-8 
12806 
rs72836561  (3%) NA NA    
CILP2 19 LDL-C rs8100204 0.137 
-0.124 
(0.019) 
1.75×10-10 
12723 
rs2228603  (7%) 
-0.067 
(0.019) 
5.7×10-4 
12723 
rs58542926  (6%) 
rs187429064  (4%) 
-0.006 
(0.019) 
0.744 
12723 
rs58542926  (6%) 
-0.064 
(0.019) 
9.9×10-4 
12723 
rs187429064  (4%) 
-0.078 
(0.019) 
5.4×10-5 
12723 
CILP2 19 TC rs8100204 0.137 
-0.149 
(0.019) 
1.12×10-14 
12819 
rs2228603  (7%) 
-0.079 
(0.019) 
3.8×10-5 
12819 
rs58542926  (6%) 
rs187429064  (4%) 
-0.011  
(0.019) 
0.565 
12819 
rs58542926  (6%) 
-0.079 
(0.019) 
4.2×10-5 
12819 
rs187429064  (4%) 
-0.093 
(0.019) 
1.3×10-6 
12819 
rs2074300  (14%) 
-0.099 
(0.019) 
3.2×10-7 
12819 
rs12151060  (14%) 
-0.125 
(0.019) 
1.0×10-10 
12819 
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Locus CHR Trait 
Testing the lead-SNP effects 
Tested lead-SNP 
rsID 
MAF 
Unconditional Conditional 
Effect 
(SE) 
p-value     
N 
Candidate SNP used as a 
single covariate in the model 
(MAF) 
Lead-SNP 
effect when 
adjusting for 
single SNP 
(SE) 
p-value   
N 
Candidate SNPs used 
jointly as covariates in 
the model 
(MAF) 
Lead-SNP 
effect when 
adjusting for 
multiple 
SNPs (SE) 
p-value   
N 
CILP2 19 TG rs58434384 0.056 
-0.158 
(0.026) 
2.06×10-9 
12807 
rs2228603  (7%) 
-0.064 
(0.026) 
0.015 
12809 
rs58542926  (6%) 
rs187429064  (4%) 
-0.047  
(0.026) 
0.075 
12809 
rs58542926  (6%) 
-0.048 
(0.026) 
0.066 
12809 
rs187429064  (4%) 
-0.147 
(0.026) 
2.5×10-8 
12809 
rs12151060  (14%) 
-0.127 
(0.026) 
1.5×10-6 
12809 
The table shows results for the lead-SNP (column rsID) before and after conditional analysis on the functional candidate variants. In case 
multiple candidate variants were observed in a locus, multiple linear regression models were fitted to explore the effect of each individual SNP 
and of all SNPs together. For CILP2 locus, result of the final model with two SNPs is represented. Results for the lead-SNP in the unconditional 
analysis are presented from the meta-analysis of Finnish subset (N = 12,834). Effect sizes are presented in s.d units. CHR: Chromosome, MAF: 
Minor allele frequency, SE: Standard error of effect estimate, N: Number of samples, HDL-C: High-density lipoprotein cholesterol, LDL-C: 
Low-density lipoprotein cholesterol, TC: Total cholesterol, TG: Triglycerides. 
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Figure legends: 
Figures 1A-B. Change in p-value after analysis conditional on the new lead-SNP and comparison of new and previously reported lead-SNP 
effect sizes and allele frequencies per locus. In both figures, each of the arrows represent one locus and trait, where significant association was 
found in our screening and in one of the previously published large-scale screening studies2,3 and the colouring is based on the linkage 
disequilibrium (LD) between the old and new lead-SNP. The red ‘*’ represents for the new low-frequency lead-SNPs. In the Figure 1A, on the 
Y-axis are the –log10 p-values, arrows starting from the p-value seen in the unconditional analysis in Finnish subset (N = 12,834) and pointing to 
the p-value in analysis conditional on the new lead-SNP. In Figure 1B, each arrow starts from established lead-SNP effect and minor allele 
frequency (MAF) and points to the corresponding values for the new lead-SNP. The effects have been estimated in the FRCoreExome9702 
sample set (N = 5,119), independent of the discovery set. Only results for loci with r2<0.4 have been presented for clarity.  
Figures 2A-B: Regional association plots of the conditional analysis in loci where the new functional candidate SNPs explain the genome-wide 
association. Figure 2A illustrates the results in SOST-DUSP3 locus for TG and Figure 2B results in CILP2 locus for TC in Finnish subset (N = 
12,834). In these figures, the first panel shows the –log10 p-value of each variant as a dot whose size reflects the effect size. The second panel 
shows the recombination rate in the area and the third panel shows the positions of genes. X-axis is the physical position in the genome. In grey 
are the association results from the unconditional analysis with green dots representing the new functional candidate SNPs. Black dots are the 
results from the conditional analysis. 
Figure 3: Proportion of total trait variance explained by the lead-SNPs and functional SNPs. The proportion of the trait variance explained by 
different SNP-sets has been estimated in independent FRCoreExome9702 sample set (N = 5,119). All lead-SNPs from the three association 
screens (Teslovich et al.2, Willer et al.3 and our screen) together with the known functional lipid SNPs (FL SNPs) and new functional candidate 
SNPs were grouped based on their allele frequency in the FRCoreExome9702 dataset to common SNPs (allele frequency > 5%) and to low-
frequency SNPs (allele frequency ≤ 5%). The variance explained by these two groups is presented with blue bars. The proportion of variance 
explained by the FL SNPs and functional candidates is presented with the red bar. !
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